Tirzepatide Cost in 2026: Every Price Point Compared

Summary: Brand tirzepatide list prices in 2026 sit between $1069 and $1086 per month, but almost nobody pays sticker. Real prices range from $25 with commercial insurance to $349 on LillyDirect Self Pay, with telehealth compounded routes still alive in the $199 to $349 range.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: brand tirzepatide in 2026 lists between $1069 and $1086 per month in pen form. Mounjaro runs about $1069, Zepbound about $1086 at the top dose tiers ^[1][2]. Most people pay far less. Commercial insurance with a manufacturer savings card cuts the bill to $25 per month. Eli Lilly's LillyDirect Self Pay program ships single-dose Zepbound vials for $349 to $599 per month depending on dose ^[3]. Compounded tirzepatide from telehealth providers still sits between $199 and $349 per month in 2026 for patients with a documented clinical justification.

This page lines up every price point in one place. If you only want the cheapest legal path for your situation, skip to the recommendation tree.

Brand list prices in 2026

The two FDA-approved tirzepatide products are made by Eli Lilly. They share an identical molecule and manufacturing process, but the FDA approved them for different indications, which is the reason the two product names exist at all.

These are wholesale acquisition costs, the published list prices that pharmacies use as a starting point. The figure on your pharmacy receipt before any insurance adjustment or coupon is almost always within a few dollars of the list price ^[1].

The two products contain exactly the same active ingredient at the same strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg per pen) ^[4]. The price difference of about $17 per month exists for billing reasons, not chemistry. Mounjaro is the diabetes label; Zepbound is the obesity and sleep apnea label. Insurers route prior authorization through different formulary lines based on the label, which is why the same molecule shows up at two prices.

What insurance actually pays

Commercial insurance coverage for tirzepatide depends entirely on the indication on your prescription and your plan's formulary.

Mounjaro for type 2 diabetes

Mounjaro is covered by roughly 80% of commercial plans, most Medicare Part D plans, and most state Medicaid programs when prescribed for type 2 diabetes. Copays typically run $25 to $100 per month for commercial plans and $0 to $50 for Medicaid. Eli Lilly's Mounjaro savings card brings the commercial copay to $25 per month for up to a 3-month supply at a time, with a $150 maximum savings per 1-month fill ^[2]. Patients on Medicare, Medicaid, Tricare, or any government plan are not eligible for that card.

Zepbound for weight loss

This is where coverage gets messy. Zepbound is approved for chronic weight management, and most commercial plans either exclude weight-loss drugs entirely or require prior authorization with documented BMI thresholds, comorbidities, and prior failed weight-loss attempts. About 30 to 40% of large employer commercial plans cover Zepbound in 2026. When covered, copays land between $25 and $300 per month. The Zepbound savings card knocks the commercial copay down to $25 per month for plans that cover the drug, with a 13-fill annual limit ^[1].

Self-funded employer plans set their own rules. Some of the largest US employers expanded Zepbound coverage in 2025 after the SURMOUNT-OSA trial extended the FDA label to obstructive sleep apnea, opening a second medical indication beyond pure weight loss. Other employers tightened restrictions or dropped weight-loss coverage entirely to control costs. There is no national pattern. Call your plan.

Zepbound for obstructive sleep apnea

In 2024 the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea in adults with obesity. This unlocked coverage from plans that exclude weight-loss drugs but cover OSA treatments. If you have a documented OSA diagnosis (typically a positive sleep study with an AHI of 15 or higher) and a BMI of 30 or higher, your prescriber can write Zepbound under the OSA indication. Coverage rates under this indication are higher than for pure weight loss, although prior authorization is still common.

Does Blue Cross Blue Shield cover tirzepatide?

BCBS is not one insurer. Each state's Blue Cross Blue Shield plan sets its own formulary. As of 2026, most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization, copays around $25 to $75. Zepbound coverage is split: BCBS plans in Michigan, Massachusetts, and Illinois typically cover it with PA; many southern and western BCBS plans exclude weight-loss drugs entirely. Federal Employee Program (FEP) Blue plans cover Zepbound nationally as of 2025. Always check your specific plan's drug list.

Does Tricare cover tirzepatide?

Tricare covers Mounjaro for type 2 diabetes with prior authorization across all plan types (Prime, Select, For Life). Tricare covers Zepbound for chronic weight management when patients meet BMI and comorbidity criteria, with prior authorization. Active-duty service members and retirees pay standard Tricare formulary copays.

LillyDirect Self Pay: the manufacturer's cash-pay program

LillyDirect Self Pay is Eli Lilly's direct-to-patient pharmacy launched in January 2024 and repriced repeatedly through 2025 and 2026 in response to the compounded tirzepatide market. It sells single-dose Zepbound vials, not the auto-injector pens, at a discounted self-pay price.

To qualify, you must be uninsured or insured but without Zepbound coverage, have a valid prescription, and be willing to use a single-dose vial with the included syringe rather than the pre-filled pen ^[3]. Lilly's online platform will connect you to a telehealth prescriber if you do not already have one. Home delivery is included.

The vials contain identical FDA-approved Lilly tirzepatide. The price difference between pen and vial reflects the simpler packaging and the absence of the insurance billing chain. Medicare and Medicaid beneficiaries are not eligible for the self-pay rate; they use their plan's pharmacy benefit, although they can technically pay out of pocket if they choose to.

LillyDirect does not sell Mounjaro at a cash discount. The $1069 list price stands for Mounjaro if you have no coverage. GoodRx and similar discount cards can shave 3 to 8% off the retail figure, bringing Mounjaro to roughly $1010 to $1040 at major chains.

The savings card path

If you have commercial insurance, this is almost always the cheapest legal route.

• Mounjaro savings card: $25 per month copay for patients with commercial insurance that covers Mounjaro. $150 maximum savings per 1-month fill, $1800 annual cap ^[2]. Activates online at mounjaro.com.
• Zepbound savings card with coverage: $25 per month copay for commercial plans that cover Zepbound. Limited to 13 fills per year ^[1]. Activates at zepbound.lilly.com.
• Zepbound savings card without coverage: if your commercial plan does not cover Zepbound, the card brings the price down to roughly $650 per month, which is still worse than LillyDirect Self Pay. Skip the card and use LillyDirect Self Pay at $349 to $599 instead.

You cannot stack a savings card with Medicare, Medicaid, Tricare, VA, or any other government insurance. Federal law prohibits it. If you are on a government plan, your copay is set by the plan's formulary tier.

Medicare and Medicaid in 2026

Medicare Part D covers Mounjaro for type 2 diabetes. Copays vary by plan and tier but typically run $0 to $100 per month. Catastrophic coverage now caps annual out-of-pocket Part D spending at $2000 per year as of the Inflation Reduction Act's 2025 phase-in, so even high-cost months stop counting once you hit that cap ^[5].

Will tirzepatide be covered by Medicare for weight loss? Not as of 2026. Medicare statute (the Medicare Modernization Act of 2003) prohibits Part D coverage of drugs prescribed for weight loss alone. Zepbound is not covered when prescribed under the obesity indication. The 2024 FDA label expansion to obstructive sleep apnea created a path: Part D plans can cover Zepbound for patients with documented moderate-to-severe OSA and obesity. Roughly half of Part D plans added Zepbound to their formularies under the OSA indication for 2026. Coverage and copays vary widely.

Medicaid coverage of tirzepatide is state by state. All states cover Mounjaro for type 2 diabetes. Zepbound coverage for weight loss is patchy. California, Michigan, Minnesota, and a handful of other state Medicaid programs cover Zepbound with prior authorization. Most states do not. Check your state Medicaid drug formulary directly; the list changes year to year.

Compounded tirzepatide: what changed in 2025 and 2026

Compounded tirzepatide had a different regulatory ride than compounded semaglutide. From 2022 through late 2024, tirzepatide was on the FDA shortage list, and 503A and 503B pharmacies produced large volumes of compounded tirzepatide for the telehealth market. Cash prices ran $199 to $399 per month.

The FDA declared the tirzepatide shortage resolved in late 2024. A court-ordered grace period followed for 503B outsourcing facilities, ending in March 2025. After that date, 503B facilities can no longer mass-produce essentially copy versions of FDA-approved tirzepatide. 503A pharmacies retained the right to compound for individual patients with a documented clinical justification, such as an excipient allergy, an unusual dose, or a combination formulation (tirzepatide with B12 or pyridoxine).

What this means in practice for 2026:

• Compounded tirzepatide is still legally available, but only as patient-specific compounded preparations with a clinical justification.
• Standard-formulation compounded tirzepatide from a national 503B telehealth provider is no longer permitted under FDA enforcement policy.
• Cash prices for clinically justified compounding run $199 to $349 per month at the major surviving telehealth providers (MEDVi, Mochi Health, Henry Meds, Hers, Ro, Eden), with starter doses cheapest and 12.5 to 15 mg doses adding $30 to $80 per month.
• Generic tirzepatide does not exist. Lilly holds composition-of-matter patents on tirzepatide that extend into the mid-2030s. No FDA-approved generic version is permitted in the US until then. "Generic tirzepatide" sold online is either compounded tirzepatide or a research peptide, neither of which is a true generic in the FDA sense.

If you were on compounded tirzepatide in 2024 and your telehealth provider has not switched you to a clinically justified preparation, expect a forced transition to LillyDirect vials or brand Zepbound during your next refill cycle.

Telehealth subscription pricing in 2026

Telehealth providers are still in the mix, but most have pivoted from selling 503B-produced compounded product to handling clinically justified 503A compounding plus prescribing and shipping logistics for brand Zepbound and LillyDirect vials.

The economics for cash-pay patients shifted in 2025. Before LillyDirect dropped to $349 to $499 for vials, telehealth was the only realistic way to get tirzepatide for under $500 a month. Now that Lilly sells Zepbound vials direct at $349 (starter) and $499 (most dose tiers), the gap between telehealth compounded ($199 to $349) and brand vial ($349 to $499) has narrowed enough that some patients move to brand. Telehealth providers compensate by bundling clinical care, dietitian access, and labs.

Tirzepatide versus semaglutide cost in 2026

Patients shopping for the cheapest GLP-1 path compare tirzepatide to semaglutide. The pricing structures are similar but not identical.

The two molecules differ in pharmacology (tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a pure GLP-1 agonist) and in head-to-head trial data tirzepatide produces more weight loss at maximum doses. Pricing parity at the cheapest insured copay tier is no accident; both manufacturers compete for the same commercial coverage and price their savings cards accordingly. The biggest practical price difference in 2026 is on the cash-pay side. Lilly's vial program ($349 starter, $499 most doses) is cheaper than Novo's Wegovy NovoCare ($499 flat). For uninsured patients with no clinical contraindication to either drug, tirzepatide via LillyDirect is the cheaper brand path.

Why tirzepatide is so expensive in the first place

A short answer to a question most people ask: tirzepatide manufacturing costs are estimated at $5 to $25 per month of supply at the active ingredient level. The retail price is a function of US drug pricing structure, not production cost.

The three factors that drive the list price:

1. Patent protection. Eli Lilly holds composition-of-matter and formulation patents on tirzepatide that extend into the mid-2030s. No generic competition is permitted in the US until those patents expire or are invalidated.
2. Lack of price negotiation. Tirzepatide was added to the Medicare drug price negotiation list for the 2027 negotiation cycle, meaning negotiated prices will appear no earlier than 2027 implementation. Until then, Medicare pays close to list.
3. Demand-driven pricing. The clinical results in SURMOUNT and SURPASS trials drove demand that outstrips supply at any price below $1000. Lilly has had no commercial reason to cut list prices for insured patients, only for cash-pay segments where compounded competition forced the LillyDirect launch.

European list prices for the same product are roughly 60 to 80% lower. UK NHS contracts Mounjaro and Zepbound at the equivalent of roughly £150 to £200 per month. The US price difference is structural, not cost based.

The cheapest legal path in 2026

Pick the branch that matches your situation.

If you have commercial insurance

1. Ask your prescriber whether your plan covers tirzepatide for your indication (diabetes versus weight loss versus OSA).
2. If covered, get the prescription filled and apply the manufacturer savings card. Expected cost: $25 per month for either Mounjaro or Zepbound.
3. If not covered for weight loss, ask the prescriber whether you qualify under the OSA indication (documented moderate-to-severe OSA plus BMI 30+). Many plans that exclude weight-loss drugs cover OSA treatments.
4. If still not covered, move to LillyDirect Self Pay vials at $349 to $599 per month, or to a different drug your plan does cover.

If you have Medicare

1. Mounjaro is a covered Part D drug for type 2 diabetes. Expect $0 to $100 monthly copays depending on plan.
2. Zepbound is covered only for obstructive sleep apnea. Get the OSA diagnosis documented with a sleep study. Expect $50 to $200 monthly copays.
3. The 2025 $2000 Part D out-of-pocket cap protects you on the high end.

If you have Medicaid

1. All state Medicaid plans cover Mounjaro for type 2 diabetes. Copay is typically $0 to $4.
2. A handful of states cover Zepbound for weight loss. Check your state formulary.
3. Where not covered, ask your prescriber about patient assistance through Lilly Cares, which provides free Zepbound to qualifying low-income patients with no insurance.

If you are uninsured

1. The LillyDirect Self Pay vial program at $349 (2.5 mg) and $499 (most dose tiers) is the cheapest legal brand source of tirzepatide. Sign up at lillydirect.com.
2. For type 2 diabetes, Mounjaro pen at retail is $1069. There is no manufacturer cash-pay rate for the Mounjaro pen. GoodRx may bring it to $1010 to $1040 at some pharmacies.
3. Patient-specific compounded tirzepatide from a verified 503A pharmacy with documented clinical need runs $199 to $349 per month. Verify the pharmacy is state-licensed and that your prescriber documents the clinical justification.
4. Apply for Lilly Cares Foundation Patient Assistance if your income is at or below 400% of the federal poverty level. Approved patients receive Mounjaro or Zepbound free.

State by state pricing notes

Brand list prices do not vary by state. Insurance copays and Medicaid coverage do, but the rules are set by your plan, not your location. The few state-specific cost differences:

• Texas, Florida, Arizona: large telehealth markets with high competition among compounding pharmacies historically meant lower compounded prices. Post-shortage that gap has narrowed but Texas still has the largest concentration of 503A pharmacies serving the tirzepatide market.
• California, New York, Massachusetts: state-regulated insurance markets often require broader weight-loss drug coverage. Commercial copays for Zepbound run lower than national averages.
• Michigan, Illinois, Minnesota: state Medicaid programs cover Zepbound for weight loss with prior authorization.
• High-cost-of-living states: retail cash prices at pharmacy chains can run 3 to 5% above the national list price. Costco consistently offers the lowest brand pen retail price at roughly $1049 to $1089 per month, and you do not need a Costco membership to use the pharmacy in most states.

The variation is real but small compared to the differences between insurance, LillyDirect, and compounded paths. Your situation matters more than your zip code.

Common questions about tirzepatide cost

How much does tirzepatide cost per month without insurance in 2026?

LillyDirect Self Pay sells Zepbound vials for $349 (starter) and $499 (most doses). Brand Mounjaro or Zepbound pens at retail are $1069 to $1086. Patient-specific compounded tirzepatide runs $199 to $349 where clinically justified.

What is the cheapest tirzepatide path in 2026?

For commercial insurance holders, the manufacturer savings card brings Mounjaro or Zepbound to $25 per month. For uninsured patients, LillyDirect vials at $349 to $499 are the cheapest brand option, and patient-specific compounded tirzepatide via telehealth starts around $199.

How much does tirzepatide cost with insurance?

With commercial insurance that covers tirzepatide plus the manufacturer savings card, the typical copay is $25 per month. Without the savings card, formulary copays run $25 to $300 depending on tier placement. Coinsurance plans paying a percentage of list can run higher.

Does Medicare cover tirzepatide?

Medicare Part D covers Mounjaro for type 2 diabetes with copays typically $0 to $100. Medicare covers Zepbound only when prescribed for obstructive sleep apnea, not for weight loss alone. The Inflation Reduction Act caps annual Part D out-of-pocket spending at $2000.

Does Medicaid cover tirzepatide?

All state Medicaid programs cover Mounjaro for type 2 diabetes. Zepbound coverage for weight loss varies. California, Michigan, Minnesota, and several other states cover Zepbound with prior authorization. Most states do not cover Zepbound at all.

Does Blue Cross Blue Shield cover tirzepatide?

Most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization. Zepbound coverage varies dramatically by state: BCBS Michigan, Illinois, and Massachusetts typically cover it, while many southern and western plans exclude weight-loss drugs. The Federal Employee Program Blue plan covers Zepbound nationally.

Does Tricare cover tirzepatide?

Tricare covers Mounjaro for type 2 diabetes with prior authorization across all plan types. Tricare covers Zepbound for chronic weight management when patients meet BMI and comorbidity criteria, with prior authorization. Copays follow Tricare formulary tiers.

How much does Mounjaro cost with the savings card?

With commercial insurance and the Mounjaro savings card, the copay is $25 per month for up to a 3-month supply at a time, capped at $150 per 1-month fill and $1800 per year. Patients on government insurance are not eligible.

How much does Zepbound cost with the savings card?

The Zepbound savings card brings the commercial insurance copay to $25 per month for plans that cover Zepbound, limited to 13 fills per year. If your plan does not cover Zepbound, LillyDirect Self Pay at $349 to $499 is a better deal than the card.

Is there a generic tirzepatide?

No. Eli Lilly holds patents on tirzepatide that extend into the mid-2030s, and no FDA-approved generic exists. "Generic tirzepatide" sold online refers to either compounded tirzepatide from a state-licensed pharmacy or research peptides, neither of which is a true generic in the FDA sense.

How much does compounded tirzepatide cost in 2026?

Patient-specific compounded tirzepatide via telehealth runs $199 to $349 per month at major providers, depending on dose and bundled services. Mass-market compounded tirzepatide is no longer permitted since the FDA shortage resolved in 2024 and 503B production ended in March 2025.

Why is tirzepatide so expensive in the United States?

US tirzepatide prices reflect patent protection through the mid-2030s, no Medicare price negotiation until at least 2027, and demand that exceeds supply at any price below $1000. European list prices for the same drug are 60 to 80% lower.

Is tirzepatide tax deductible?

Yes, when prescribed for a medical condition. Tirzepatide costs qualify as itemized medical expenses subject to the 7.5% AGI threshold on a federal return. Save pharmacy receipts and any telehealth fees attributable to the prescription.

What this article does not cover

This page is the pricing reference. Adjacent questions, like which specific telehealth provider is the best fit, how to file a prior authorization appeal, and which dose to start at, live on their own pages on this site. Use the search to find them. If you only remember one thing from this page, it is that the brand list price is rarely what anyone actually pays, and the cheapest legal path in 2026 depends entirely on what insurance, if any, you carry.